Clinical Edge Journal Scan

Worse outcomes among elderly patients with RA undergoing percutaneous coronary intervention


 

Key clinical point: The risk for all-cause mortality is higher among elderly patients with vs without rheumatoid arthritis (RA) who undergo percutaneous coronary intervention (PCI), with the risk being the highest among those with elderly-onset RA (disease presentation after 65 years of age).

Major finding: During the 10-year follow-up, all-cause mortality-associated survival rates were significantly lower in patients with vs without RA (53.7% vs 58.3%; log-rank P < .001) and in patients with elderly-onset vs young-onset RA (48.1% vs 73.7%; log-rank P < .001). Trends were similar for cardiovascular disease-associated survival rates (all log-rank P < .001).

Study details: This was a population-based retrospective cohort study including 74,623 patients age 65 years with (n = 14,074) or without (n = 60,549) RA who were diagnosed with acute coronary syndrome and underwent PCI.

Disclosures: This study was funded by Soonchunhyang University, South Korea, and the Asan Foundation, South Korea. The authors declared no conflicts of interest.

Source: Kim BY et al. Outcomes of percutaneous coronary intervention in elderly patients with rheumatoid arthritis: A nationwide population-based cohort study. Healthcare (Basel). 2023;11(10):1381 (May 10). Doi: 10.3390/healthcare11101381

Recommended Reading

Investigational drug peresolimab shows efficacy in patients with RA
MDedge Rheumatology
Strong link between polycyclic aromatic hydrocarbons and raised rheumatoid arthritis risk
MDedge Rheumatology
Joint damage repair: A rare phenomenon in early RA
MDedge Rheumatology
Tofacitinib withdrawal not a universal option for all patients with RA in remission
MDedge Rheumatology
Factors guiding sustained remission after withdrawal of combination therapy in RA
MDedge Rheumatology
HPV infection, HPV immunization, and RA prevalence: What is the link?
MDedge Rheumatology
No evidence to indicate significantly higher risk for cancer with JAKi vs bDMARD in RA
MDedge Rheumatology
Mendelian randomization study supports causal association between RA and coronary atherosclerosis
MDedge Rheumatology
Comparable efficacy of TNFi and IL-6Ri in b/tsDMARD-experienced patients with RA
MDedge Rheumatology
RA, seropositivity, and risk for Parkinson disease: Is there a link?
MDedge Rheumatology